Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transactions
SEC Form 4 Filing
CEO Craig Collard reports the vesting of restricted stock units into common stock.
Summary
- On July 19, 2024, Craig Collard, CEO of Heron Therapeutics, reported the vesting of 13,797 restricted stock units into common stock.
- These restricted stock units convert into common stock on a quarterly basis.
- Following the transaction, Collard directly owns 276,590 shares of common stock and 193,156 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency to investors regarding the transactions of company leadership.
Stakeholder Impact
- The vesting of restricted stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for the restricted stock units. |
| 07/19/2024 | Date of transaction: vesting of restricted stock units. |
| 07/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.